Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Aveo Pharmaceuticals, OSI, Peptech deal

Aveo and OSIP partnered to develop therapeutics that target mechanisms of epithelial-mesenchymal transition to treat

Read the full 158 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE